These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 36298524)

  • 1. Will Bivalent Vaccination against COVID-19 Increase the Desire for COVID-19 Vaccination among Poles?
    Babicki M
    Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attitudes of Poles towards the COVID-19 Vaccine Booster Dose: An Online Survey in Poland.
    Babicki M; Mastalerz-Migas A
    Vaccines (Basel); 2022 Jan; 10(1):. PubMed ID: 35062729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reasons for Receiving or Not Receiving Bivalent COVID-19 Booster Vaccinations Among Adults - United States, November 1-December 10, 2022.
    Sinclair AH; Taylor MK; Weitz JS; Beckett SJ; Samanez-Larkin GR
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(3):73-75. PubMed ID: 36656784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
    Külper-Schiek W; Piechotta V; Pilic A; Batke M; Dreveton LS; Geurts B; Koch J; Köppe S; Treskova M; Vygen-Bonnet S; Waize M; Wichmann O; Harder T
    Front Immunol; 2022; 13():940562. PubMed ID: 36091023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status - COVID-NET, 14 States, July 2021-January 2022.
    Taylor CA; Whitaker M; Anglin O; Milucky J; Patel K; Pham H; Chai SJ; Alden NB; Yousey-Hindes K; Anderson EJ; Teno K; Reeg L; Como-Sabetti K; Bleecker M; Barney G; Bennett NM; Billing LM; Sutton M; Talbot HK; McCaffrey K; Havers FP;
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(12):466-473. PubMed ID: 35324880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
    Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
    EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines.
    Ye ZW; Fan Y; Tang K; Ong CP; Luo C; Chung HL; Leong TL; Liang R; Lui WY; Zhou R; Cheng Y; Lu L; Cheung PH; Chan JF; Chen Z; Yuen KY; Yuan S; To KK; Jin DY
    Int J Biol Sci; 2022; 18(12):4781-4791. PubMed ID: 35874942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review.
    Chenchula S; Karunakaran P; Sharma S; Chavan M
    J Med Virol; 2022 Jul; 94(7):2969-2976. PubMed ID: 35246846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.
    León TM; Dorabawila V; Nelson L; Lutterloh E; Bauer UE; Backenson B; Bassett MT; Henry H; Bregman B; Midgley CM; Myers JF; Plumb ID; Reese HE; Zhao R; Briggs-Hagen M; Hoefer D; Watt JP; Silk BJ; Jain S; Rosenberg ES
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):125-131. PubMed ID: 35085222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022.
    Prasad N; Derado G; Nanduri SA; Reses HE; Dubendris H; Wong E; Soe MM; Li Q; Dollard P; Bagchi S; Edwards J; Shang N; Budnitz D; Bell J; Verani JR; Benin A; Link-Gelles R; Jernigan J; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2022 May; 71(18):633-637. PubMed ID: 35511708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and Effectiveness of Primary and Booster Vaccine Combination Strategies during Periods of SARS-CoV-2 Delta and Omicron Variants.
    Moghnieh R; El Hajj C; Abdallah D; Jbeily N; Bizri AR; Sayegh MH
    Vaccines (Basel); 2022 Sep; 10(10):. PubMed ID: 36298460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-Person Schooling Amidst Children's COVID-19 Vaccination: Exploring Parental Perceptions Just after Omicron Variant Announcement.
    Aljamaan F; Alhaboob A; Saddik B; Bassrawi R; Assiri R; Saeed E; Alhasan K; Alenezi S; Alarabi M; Alrabiaah A; Alkriadees Y; Al-Saud N; Alenazi B; Rabaan AA; Halwani R; AlZamil F; Barry M; Memish ZA; Al-Tawfiq JA; Temsah MH
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632524
    [No Abstract]   [Full Text] [Related]  

  • 13. The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.
    Zou Y; Huang D; Jiang Q; Guo Y; Chen C
    Front Public Health; 2022; 10():940956. PubMed ID: 35910897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Quick Displacement of the SARS-CoV-2 variant Delta with Omicron: Unprecedented Spike in COVID-19 Cases Associated with Fewer Admissions and Comparable Upper Respiratory Viral Loads.
    Fall A; Eldesouki RE; Sachithanandham J; Morris CP; Norton JM; Gaston DC; Forman M; Abdullah O; Gallagher N; Li M; Swanson NJ; Pekosz A; Klein EY; Mostafa HH
    medRxiv; 2022 Jan; ():. PubMed ID: 35118480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of a Second COVID-19 Vaccine Booster Dose Against Infection, Hospitalization, or Death Among Nursing Home Residents - 19 States, March 29-July 25, 2022.
    McConeghy KW; White EM; Blackman C; Santostefano CM; Lee Y; Rudolph JL; Canaday D; Zullo AR; Jernigan JA; Pilishvili T; Mor V; Gravenstein S
    MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(39):1235-1238. PubMed ID: 36173757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attitudes of Parents with Regard to Vaccination of Children against COVID-19 in Poland. A Nationwide Online Survey.
    Babicki M; Pokorna-Kałwak D; Doniec Z; Mastalerz-Migas A
    Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urban monitoring, evaluation and application of COVID-19 listed vaccine effectiveness: a health code blockchain study.
    Wang T; Li C; Li H; Li Z
    BMJ Open; 2022 Jul; 12(7):e057281. PubMed ID: 35831042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence - 25 U.S. Jurisdictions, April 4-December 25, 2021.
    Johnson AG; Amin AB; Ali AR; Hoots B; Cadwell BL; Arora S; Avoundjian T; Awofeso AO; Barnes J; Bayoumi NS; Busen K; Chang C; Cima M; Crockett M; Cronquist A; Davidson S; Davis E; Delgadillo J; Dorabawila V; Drenzek C; Eisenstein L; Fast HE; Gent A; Hand J; Hoefer D; Holtzman C; Jara A; Jones A; Kamal-Ahmed I; Kangas S; Kanishka F; Kaur R; Khan S; King J; Kirkendall S; Klioueva A; Kocharian A; Kwon FY; Logan J; Lyons BC; Lyons S; May A; McCormick D; ; Mendoza E; Milroy L; O'Donnell A; Pike M; Pogosjans S; Saupe A; Sell J; Smith E; Sosin DM; Stanislawski E; Steele MK; Stephenson M; Stout A; Strand K; Tilakaratne BP; Turner K; Vest H; Warner S; Wiedeman C; Zaldivar A; Silk BJ; Scobie HM
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):132-138. PubMed ID: 35085223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.